Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
The Oncologist|June 24, 2018
Brain Metastases from Adult Sarcoma: Prognostic Factors and Impact of Treatment. A Retrospective Analysis from the French Sarcoma Group (GSF/GETO)Loïc Chaigneau, Anna Patrikidou, Isabelle Ray-Coquard, et al.
European Journal of Cancer (Oxford, England : 1990)|October 7, 2021
Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales)Mathilde Cancel, Gaelle Fromont, Cyriac Blonz, et al.
European Journal of Cancer (Oxford, England : 1990)|December 17, 2022
Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance statusLucía Carril-Ajuria, Emeline Colomba, Carmen Romero-Ferreiro, et al.
European Urology|June 30, 2021
Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al.
JAMA Oncology|February 1, 2019
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical TrialStéphane Oudard, Igor Latorzeff, Armelle Caty, et al.
Vaccine|August 23, 2025
Humoral immune response to Covid-19 vaccination in patients with cancer - Results from the ANRS0001S COV-POPART studyLiem Binh Luong Nguyen, Lyvia Magloire, Alexis François, et al.
European Journal of Cancer (Oxford, England : 1990)|November 29, 2011
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trialKarim Fizazi, Francois Lesaunier, Remy Delva, et al.
The New England Journal of Medicine|June 5, 2018
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell CarcinomaArnaud Méjean, Alain Ravaud, Simon Thezenas, et al.
The Lancet. Oncology|June 2, 2015
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trialKarim Fizazi, Laura Faivre, François Lesaunier, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2026
Survival modelling of relapse-free survival and competing-risk analysis in patients with high-risk localized prostate cancer treated in GETUG-12Cécile Vicier, Farah Erdogan, Nedjla Allouache, et al.
Pageof 5